For four generations, Rome’s Angelini family has built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market. https://t.co/RXhiT5eH4a📸: Angelini Pharma https://t.co/U8ET3v9jNl ...

India's generic drugmakers shouldn't rush to move manufacturing to the US, writes @julianaliu. Tariffs may never fully materialize (via @opinion) https://t.co/GK2BdM3Be1 ...

“What was clear from the beginning is that the U.S., in the pharmaceutical space, is mandatory,” Sergio Marullo di Condojanni, CEO of Angelini Holding and Angelini Pharma, tells Forbes.Read the full story on how Rome’s Angelini family bought its way into the U.S. market: https://t.co/GCuDFm4IIu📸: Angelini Pharma ...